## CORRECTION

**Open Access** 



# Correction to: PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse

Bingxin Zheng<sup>1,2†</sup>, Tingting Ren<sup>1,2†</sup>, Yi Huang<sup>1,2</sup>, Kunkun Sun<sup>1,3</sup>, Shidong Wang<sup>1,2</sup>, Xing Bao<sup>1,2</sup>, Kuisheng Liu<sup>1,2</sup> and Wei Guo<sup>1,2\*</sup>

### Erratum

The original article [1] contained an error in Table 1 whereby the 'Positive' column in the 'PD-L1' Tumor type group of columns was mistakenly included at the beginning of the 'PD-L2' Tumor type group of columns.

This error has now been corrected. Furthermore, this error was not the fault of the authors, and was instead mistakenly carried forward by the production team that handled this article.

#### Author details

<sup>1</sup>Musculoskeletal Tumor Center, Peking University People's Hospital, No. 11 Xizhimen South Street, Beijing 100044, People's Republic of China. <sup>2</sup>Beijing Key Laboratory of Musculoskeletal Tumor, Beijing, People's Republic of China. <sup>3</sup>Department of Pathology, Peking University People's Hospital, Beijing, People's Republic of China.

#### Received: 23 February 2018 Accepted: 23 February 2018 Published online: 12 March 2018

#### Reference

 Zheng B. PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse. J Hematol Oncol. 2018;11:16.

\* Correspondence: bonetumor@pku.edu.cn

<sup>†</sup>Equal contributors

<sup>1</sup>Musculoskeletal Tumor Center, Peking University People's Hospital, No. 11 Xizhimen South Street, Beijing 100044, People's Republic of China <sup>2</sup>Beijing Key Laboratory of Musculoskeletal Tumor, Beijing, People's Republic of China

Full list of author information is available at the end of the article



© The Author(s). 2018 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Tumor	Ν	PD-L1 <i>N</i> (%)					PD-L2 N (%)					PD-1 <i>N</i> (%)				
		0	1+	2+	3+	Positive	0	1+	2+	3+	Positive	0	1+	2+	3+	Positive
Musculoskeletal tumor	234	179	35	10	10	55 (23.5%)	168	49	8	9	66 (28.2%)	185	37	5	7	49 (20.9%)
Giant cell tumor	14	4	1	2	7	10 (71.4%)	7	1	1	5	7 (50.0%)	6	1	2	5	8 (57.1%)
Osteosarcoma	62	40	17	3	2	22 (35.5%)	36	21	3	2	26 (41.9%)	45	15	1	1	17 (27.4%)
Synovial sarcoma	127	107	16	3	1	20 (15.7%)	101	22	2	2	26 (20.5%)	103	21	2	1	24 (18.9%)
Chondrosarcoma	31	28	1	2	0	3 (9.7%)	24	5	2	0	7 (22.6%)	31	0	0	0	0
Conventional chondrosarcoma	27	27	0	0	0	0	21	4	2	0	6 (22.2%)	27	0	0	0	0
Dedifferentiated chondrosarcoma	4	1	1	2	0	3 (75.0%)	3	1	0	0	1 (25.0%)	4	0	0	0	0

Table 1 Expression of PD-L1, PD-L2, and PD-1 in musculoskeletal tumors